Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor Associated with Worse Overall Survival Among Older Adults with Cancer
Findings from a population-level cohort study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
EMA Recommends Extension of Indications for Cemiplimab
New indication concerns a combination with platinum‐based chemotherapy for the first‐line treatment of NSCLC expressing PD-L1 in ≥ 1% of tumour cells, with no EGFR, ALK or ROS1 aberrations
Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously Treated with an ARPI, and Not Progressing After Subsequent Taxane Treatment
Findings from the SAKK 08/16
EMA Recommends Granting a Marketing Authorisation for Ivosidenib
It is recommended for the treatment of newly diagnosed acute myeloid leukaemia and for the treatment of locally advanced or metastatic cholangiocarcinoma
Mediterranean Diet Associated with a Higher Probability of Response in Patients with Advanced Melanoma Treated with Immune Checkpoint Blockade
Findings from a prospective multicentre cohort study
Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Findings from post hoc subgroup analyses of the ARASENS study
Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive Early Breast Cancer Treated with Adjuvant Endocrine Therapy
Findings from the PRIME II study
Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens in Patients with Triple-Class–Exposed Relapsed and Refractory Multiple Myeloma
Findings from the KarMMa-3 study
Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS Compared to Placebo in Patients with Localised RCC at High Risk of Recurrence After Nephrectomy
Findings from part A of the CheckMate 914 study
Sotorasib Shows Increase in PFS and a More Favourable Safety Compared with Docetaxel in Patients with Previously Treated Advanced KRASG12C-mutated NSCLC
Findings from the CodeBreaK 200 study
FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
Efficacy for the regular approval was evaluated in GARNET study
Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients with Small Peripheral NSCLC and Pathologically Confirmed Node-Negative Disease
Findings from the CALGB 140503 study